药物对比
Teplizumab vs Repaglinide
Teplizumab 延缓高危患者的3期1型糖尿病；Repaglinide 刺激胰岛素分泌，用于2型糖尿病。比较作用机制、给药途径和安全性。
此页面暂无可用的对比维度。
临床背景
This comparison occurs when distinguishing immunotherapy to delay type 1 diabetes from oral insulin secretagogues for type 2 diabetes.
结论
Neither drug is universally better as they address unrelated diabetes conditions with distinct mechanisms and risks.
全部药物对比